{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:35:46Z","timestamp":1793406946427,"version":"4.5.0"},"reference-count":21,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"CureDRPLA"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Rare Disease"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Dentatorubral\u2013pallidoluysian atrophy (DRPLA) is a rare, neurodegenerative disorder with no disease-modifying treatments. There is a dearth of information in the literature about the patient and caregiver experience living with DRPLA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This study aimed to (1) understand symptoms experienced by adult- and juvenile-onset DRPLA populations and their impact on daily life and (2) explore patient and caregiver treatment goals and clinical trial participation preferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>The study was a qualitative interview study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Interviews were conducted remotely with adult patients with DRPLA and caregivers. Participants described patient symptoms and the impact of those symptoms on daily life, and they discussed treatment goals and potential clinical trial participation. There were 18 patients described in the interviews with two patients and seven caregivers. Some participants were caregivers to multiple patients with DRPLA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Interview transcripts were coded for themes, and reported symptoms were summarized with descriptive statistics. Adult-onset patients ( N\u2009=\u20097) experienced difficulty with ataxia (100%), cognition (100%), fine motor skills (100%), gross motor skills (100%), speech (100%), personality changes (100%), and seizures (57%). Juvenile-onset patients ( N\u2009=\u200911) experienced difficulty with ataxia (100%), sleep (100%), speech (100%), jerking\/twitching (83%), behavior (82%), cognition (82%), fine motor skills (82%), gross motor skills (82%), sensory sensitivity (75%), and seizures (64%). When considering aspects of DRPLA to target for future treatment, patients prioritized ataxia\/mobility (100%), juvenile-onset caregivers prioritized ataxia\/mobility (60%) and independence (60%), and adult-onset caregivers prioritized personality (60%). Almost all patients (93%) would participate in a clinical trial if given the opportunity, but travel to a clinical site could pose a participation barrier for half.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study found that there are symptom domains that are relevant across the DRPLA population, but there is heterogeneity within each domain based on the age of symptom onset and disease stage, which has implications for clinical trial design.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/26330040241252447","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T02:11:26Z","timestamp":1716257486000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Understanding dentatorubral-pallidoluysian atrophy (DRPLA) symptoms and impacts on daily life: a qualitative interview study with patients and caregivers"],"prefix":"10.1177","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4769-1617","authenticated-orcid":false,"given":"Marielle G.","family":"Contesse","sequence":"first","affiliation":[{"name":"Emmes Endpoint Solutions, Emmes, 401 North Washington Street, Rockville, MD 20850-1707, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4589-1447","authenticated-orcid":false,"given":"Rebecca J.","family":"Woods","sequence":"additional","affiliation":[{"name":"Emmes Endpoint Solutions, Emmes, Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Leffler","sequence":"additional","affiliation":[{"name":"Emmes Endpoint Solutions, Emmes, Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8561-2919","authenticated-orcid":false,"given":"Silvia","family":"Prades","sequence":"additional","affiliation":[{"name":"Ataxia UK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Greenfield","sequence":"additional","affiliation":[{"name":"Ataxia UK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Compton","sequence":"additional","affiliation":[{"name":"CureDRPLA, Brooklyn, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Carroll","sequence":"additional","affiliation":[{"name":"Department of Psychology, Western Washington University, Bellingham, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"bibr1-26330040241252447","first-page":"587","volume-title":"Handbook of clinical neurology","author":"Tsuji S","year":"2012"},{"key":"bibr2-26330040241252447","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10218-6"},{"key":"bibr3-26330040241252447","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.439"},{"key":"bibr4-26330040241252447","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-008-0028-x"},{"key":"bibr5-26330040241252447","unstructured":"Prades S, Melo de Gusmao C, Grimaldi S, et al. DRPLA. In: Adam MP, Feldman J, Mirzaa GM, et al. (eds) GeneReviews\u00ae. Seattle, WA: University of Washington, Seattle, http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1491\/ (1993, accessed 28 February 2024)."},{"key":"bibr6-26330040241252447","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23167"},{"key":"bibr7-26330040241252447","doi-asserted-by":"publisher","DOI":"10.1517\/21678707.2015.1063415"},{"key":"bibr8-26330040241252447","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0718-x"},{"key":"bibr9-26330040241252447","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.05.015"},{"key":"bibr10-26330040241252447","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.38413"},{"key":"bibr11-26330040241252447","doi-asserted-by":"publisher","DOI":"10.1177\/0883073813495959"},{"key":"bibr12-26330040241252447","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-1870-2"},{"key":"bibr13-26330040241252447","volume-title":"Patient-focused drug development: collecting comprehensive and representative input","author":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, et al","year":"2018"},{"key":"bibr14-26330040241252447","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00230"},{"key":"bibr15-26330040241252447","author":"U.S. Food &amp; Drug Administration","year":"2019","journal-title":"Patient-focused drug development: methods to identify what is important to patients guidance for industry, food and drug administration staff, and other stakeholders"},{"key":"bibr16-26330040241252447","first-page":"875","volume-title":"The SAGE encyclopedia of qualitative research methods","author":"Sandelowski M","year":"2008"},{"key":"bibr17-26330040241252447","doi-asserted-by":"publisher","DOI":"10.1007\/s11135-017-0574-8"},{"key":"bibr18-26330040241252447","volume-title":"The Voice of the Patient: Living with Polyglutamine Spinocerebellar Ataxias (SCA) and Dentatorubal-Pallidoluysian Atrophy (DRPLA)","author":"National Ataxia Foundation and CureDRPLA","year":"2021"},{"key":"bibr19-26330040241252447","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-022-01393-5"},{"key":"bibr20-26330040241252447","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2012.0002"},{"key":"bibr21-26330040241252447","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182377e29"}],"container-title":["Therapeutic Advances in Rare Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/26330040241252447","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/26330040241252447","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/26330040241252447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:10:19Z","timestamp":1777597819000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/26330040241252447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":21,"alternative-id":["10.1177\/26330040241252447"],"URL":"https:\/\/doi.org\/10.1177\/26330040241252447","relation":{},"ISSN":["2633-0040","2633-0040"],"issn-type":[{"value":"2633-0040","type":"print"},{"value":"2633-0040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"26330040241252447"}}